<drug type="biotech" created="2015-11-30" updated="2016-08-17">
  <drugbank-id primary="true">DB09559</drugbank-id>
  <name>Necitumumab</name>
  <description>Necitumumab is an intravenously administered recombinant monoclonal IgG1 antibody used in the treatment of non-small cell lung cancer (NSCLC) as an EGFR antagonist. It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression. Binding of necitumumab to EGFR induces receptor internalization and degradation, thereby preventing further activation of EGFR which is beneficial in NSCLC as many patients have increased protein expression of EGFR. Necitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC). </description>
  <cas-number>906805-06-9</cas-number>
  <unii>2BT4C47RUI</unii>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <pubmed-id>20197484</pubmed-id>
        <citation>Kuenen B, Witteveen PO, Ruijter R, Giaccone G, Dontabhaktuni A, Fox F, Katz T, Youssoufian H, Zhu J, Rowinsky EK, Voest EE: A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies. Clin Cancer Res. 2010 Mar 15;16(6):1915-23. doi: 10.1158/1078-0432.CCR-09-2425. Epub 2010 Mar 2.</citation>
      </article>
      <article>
        <pubmed-id>26729188</pubmed-id>
        <citation>Garnock-Jones KP: Necitumumab: First Global Approval. Drugs. 2016 Feb;76(2):283-9. doi: 10.1007/s40265-015-0537-0.</citation>
      </article>
      <article>
        <pubmed-id>25701169</pubmed-id>
        <citation>Zhou F, Zhou C: Necitumumab for patients with non-squamous NSCLC: uninspiring results. Lancet Oncol. 2015 Mar;16(3):246-7. doi: 10.1016/S1470-2045(15)70059-8. Epub 2015 Feb 18.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference/>
  <indication>Necitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC). It is not indicated for treatment of non-squamous NSCLC. </indication>
  <pharmacodynamics/>
  <mechanism-of-action>Necitumumab is an EGFR antagonist that functions by binding to epidermal growth factor receptor (EGFR) and preventing binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression. Binding of necitumumab to EGFR induces receptor internalization and degradation.</mechanism-of-action>
  <toxicity>The poor safety profile of necitumumab has been one of the major limitations of its use.  Rigorous monitoring of the following adverse events is recommended for the use of this drug: cardiopulmonary arrest, hypomagnesia, venous and arterial thromboembolic events, dermatologic toxicities, and infusion-related reactions. Due to observations of increased toxicity and mortality in treatment of non-squamous NSCLC, necitumumab is only recommended for the treatment of squamous NSCLC in combination with cisplatin and gemcitabine. Animal studies suggest potential embryo-fetal toxicity. </toxicity>
  <metabolism/>
  <absorption/>
  <half-life>Elimination half life is approximately 14 days. </half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution>Steady state volume of distribution is 7.0 L.</volume-of-distribution>
  <clearance>14.1 mL/h</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms/>
  <products>
    <product>
      <name>Portrazza</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>0002-7716</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2015-11-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>16 mg/mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125547</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Portrazza</name>
      <ingredients>Necitumumab</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Antibodies</category>
      <mesh-id>D000906</mesh-id>
    </category>
    <category>
      <category>Antibodies, Monoclonal</category>
      <mesh-id>D000911</mesh-id>
    </category>
    <category>
      <category>Antineoplastic Agents</category>
      <mesh-id>D000970</mesh-id>
    </category>
    <category>
      <category>Antineoplastic and Immunomodulating Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Blood Proteins</category>
      <mesh-id>D001798</mesh-id>
    </category>
    <category>
      <category>Globulins</category>
      <mesh-id>D005916</mesh-id>
    </category>
    <category>
      <category>Immunoglobulins</category>
      <mesh-id>D007136</mesh-id>
    </category>
    <category>
      <category>Immunoproteins</category>
      <mesh-id>D007162</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Receptor, Epidermal Growth Factor, antagonists &amp; inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>Serum Globulins</category>
      <mesh-id>D012712</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>16 mg/mL</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="L01XC22">
      <level code="L01XC">Monoclonal antibodies</level>
      <level code="L01X">OTHER ANTINEOPLASTIC AGENTS</level>
      <level code="L01">ANTINEOPLASTIC AGENTS</level>
      <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>10:00</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>https://s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB09559.pdf?1452715789</fda-label>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00511</drugbank-id>
      <name>Acetyldigitoxin</name>
      <description>Acetyldigitoxin may decrease the cardiotoxic activities of Necitumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08879</drugbank-id>
      <name>Belimumab</name>
      <description>The risk or severity of adverse effects can be increased when Necitumumab is combined with Belimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00112</drugbank-id>
      <name>Bevacizumab</name>
      <description>Bevacizumab may increase the cardiotoxic activities of Necitumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06772</drugbank-id>
      <name>Cabazitaxel</name>
      <description>The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Necitumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>Cyclophosphamide may increase the cardiotoxic activities of Necitumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01078</drugbank-id>
      <name>Deslanoside</name>
      <description>Deslanoside may decrease the cardiotoxic activities of Necitumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01396</drugbank-id>
      <name>Digitoxin</name>
      <description>Digitoxin may decrease the cardiotoxic activities of Necitumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>Digoxin may decrease the cardiotoxic activities of Necitumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01248</drugbank-id>
      <name>Docetaxel</name>
      <description>The risk or severity of adverse effects can be increased when Docetaxel is combined with Necitumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04914</drugbank-id>
      <name>G17DT</name>
      <description>The therapeutic efficacy of G17DT can be decreased when used in combination with Necitumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05942</drugbank-id>
      <name>GI-5005</name>
      <description>The therapeutic efficacy of GI-5005 can be decreased when used in combination with Necitumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05322</drugbank-id>
      <name>INGN 201</name>
      <description>The therapeutic efficacy of INGN 201 can be decreased when used in combination with Necitumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05325</drugbank-id>
      <name>INGN 225</name>
      <description>The therapeutic efficacy of INGN 225 can be decreased when used in combination with Necitumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12843</drugbank-id>
      <name>Oleandrin</name>
      <description>Anvirzel may decrease the cardiotoxic activities of Necitumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01092</drugbank-id>
      <name>Ouabain</name>
      <description>Ouabain may decrease the cardiotoxic activities of Necitumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>The risk or severity of adverse effects can be increased when Paclitaxel is combined with Necitumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10283</drugbank-id>
      <name>Rabies vaccine</name>
      <description>The therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Necitumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05374</drugbank-id>
      <name>Rindopepimut</name>
      <description>The therapeutic efficacy of CDX-110 can be decreased when used in combination with Necitumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05440</drugbank-id>
      <name>SRP 299</name>
      <description>The therapeutic efficacy of SRP 299 can be decreased when used in combination with Necitumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06584</drugbank-id>
      <name>TG4010</name>
      <description>The therapeutic efficacy of TG4010 can be decreased when used in combination with Necitumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00072</drugbank-id>
      <name>Trastuzumab</name>
      <description>Trastuzumab may increase the cardiotoxic activities of Necitumumab.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;Sequence A
QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWIRQPPGKGLEWIGYIYYSGSTD
YNPSLKSRVTMSVDTSKNQFSLKVNSVTAADTAVYYCARVSIFGVGTFDYWGQGTLVTVS
SASTKGPSVLPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS
SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLG
GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY
NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRE
EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR
WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>
    <sequence format="FASTA">&gt;Sequence A'
QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWIRQPPGKGLEWIGYIYYSGSTD
YNPSLKSRVTMSVDTSKNQFSLKVNSVTAADTAVYYCARVSIFGVGTFDYWGQGTLVTVS
SASTKGPSVLPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS
SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLG
GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY
NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRE
EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR
WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>
    <sequence format="FASTA">&gt;Sequence B
EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPA
RFSGSGSGTDFTLTISSLEPEDFAVYYCHQYGSTPLTFGGGTKAEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</sequence>
    <sequence format="FASTA">&gt;Sequence B'
EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPA
RFSGSGSGTDFTLTISSLEPEDFAVYYCHQYGSTPLTFGGGTKAEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</sequence>
  </sequences>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D10018</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Necitumumab</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000767</id>
      <name>Epidermal growth factor receptor</name>
      <organism>Human</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>20197484</pubmed-id>
            <citation>Kuenen B, Witteveen PO, Ruijter R, Giaccone G, Dontabhaktuni A, Fox F, Katz T, Youssoufian H, Zhu J, Rowinsky EK, Voest EE: A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies. Clin Cancer Res. 2010 Mar 15;16(6):1915-23. doi: 10.1158/1078-0432.CCR-09-2425. Epub 2010 Mar 2.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P00533" source="Swiss-Prot">
    <name>Epidermal growth factor receptor</name>
    <general-function>Ubiquitin protein ligase binding</general-function>
    <specific-function>Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, amphiregulin, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin.Isoform 2 may act as an antagonist of EGF action.</specific-function>
    <gene-name>EGFR</gene-name>
    <locus>7p12</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>646-668</transmembrane-regions>
    <signal-regions>1-24</signal-regions>
    <theoretical-pi>6.67</theoretical-pi>
    <molecular-weight>134276.185</molecular-weight>
    <chromosome-location>7</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3236</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>EGFR</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X00588</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>757924</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1797</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P00533</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>EGFR_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>2.7.10.1</synonym>
      <synonym>ERBB</synonym>
      <synonym>ERBB1</synonym>
      <synonym>HER1</synonym>
      <synonym>Proto-oncogene c-ErbB-1</synonym>
      <synonym>Receptor tyrosine-protein kinase erbB-1</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001530|Epidermal growth factor receptor
MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEV
VLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALA
VLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDF
QNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGC
TGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYV
VTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFK
NCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAF
ENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKL
FGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCN
LLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVM
GENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVV
ALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGS
GAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGI
CLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAA
RNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSY
GVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPK
FRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQ
QGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTED
SIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLN
TVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRV
APQSSEFIGA</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0019007|Epidermal growth factor receptor (EGFR)
ATGCGACCCTCCGGGACGGCCGGGGCAGCGCTCCTGGCGCTGCTGGCTGCGCTCTGCCCG
GCGAGTCGGGCTCTGGAGGAAAAGAAAGTTTGCCAAGGCACGAGTAACAAGCTCACGCAG
TTGGGCACTTTTGAAGATCATTTTCTCAGCCTCCAGAGGATGTTCAATAACTGTGAGGTG
GTCCTTGGGAATTTGGAAATTACCTATGTGCAGAGGAATTATGATCTTTCCTTCTTAAAG
ACCATCCAGGAGGTGGCTGGTTATGTCCTCATTGCCCTCAACACAGTGGAGCGAATTCCT
TTGGAAAACCTGCAGATCATCAGAGGAAATATGTACTACGAAAATTCCTATGCCTTAGCA
GTCTTATCTAACTATGATGCAAATAAAACCGGACTGAAGGAGCTGCCCATGAGAAATTTA
CAGGAAATCCTGCATGGCGCCGTGCGGTTCAGCAACAACCCTGCCCTGTGCAACGTGGAG
AGCATCCAGTGGCGGGACATAGTCAGCAGTGACTTTCTCAGCAACATGTCGATGGACTTC
CAGAACCACCTGGGCAGCTGCCAAAAGTGTGATCCAAGCTGTCCCAATGGGAGCTGCTGG
GGTGCAGGAGAGGAGAACTGCCAGAAACTGACCAAAATCATCTGTGCCCAGCAGTGCTCC
GGGCGCTGCCGTGGCAAGTCCCCCAGTGACTGCTGCCACAACCAGTGTGCTGCAGGCTGC
ACAGGCCCCCGGGAGAGCGACTGCCTGGTCTGCCGCAAATTCCGAGACGAAGCCACGTGC
AAGGACACCTGCCCCCCACTCATGCTCTACAACCCCACCACGTACCAGATGGATGTGAAC
CCCGAGGGCAAATACAGCTTTGGTGCCACCTGCGTGAAGAAGTGTCCCCGTAATTATGTG
GTGACAGATCACGGCTCGTGCGTCCGAGCCTGTGGGGCCGACAGCTATGAGATGGAGGAA
GACGGCGTCCGCAAGTGTAAGAAGTGCGAAGGGCCTTGCCGCAAAGTGTGTAACGGAATA
GGTATTGGTGAATTTAAAGACTCACTCTCCATAAATGCTACGAATATTAAACACTTCAAA
AACTGCACCTCCATCAGTGGCGATCTCCACATCCTGCCGGTGGCATTTAGGGGTGACTCC
TTCACACATACTCCTCCTCTGGATCCACAGGAACTGGATATTCTGAAAACCGTAAAGGAA
ATCACAGGGTTTTTGCTGATTCAGGCTTGGCCTGAAAACAGGACGGACCTCCATGCCTTT
GAGAACCTAGAAATCATACGCGGCAGGACCAAGCAACATGGTCAGTTTTCTCTTGCAGTC
GTCAGCCTGAACATAACATCCTTGGGATTACGCTCCCTCAAGGAGATAAGTGATGGAGAT
GTGATAATTTCAGGAAACAAAAATTTGTGCTATGCAAATACAATAAACTGGAAAAAACTG
TTTGGGACCTCCGGTCAGAAAACCAAAATTATAAGCAACAGAGGTGAAAACAGCTGCAAG
GCCACAGGCCAGGTCTGCCATGCCTTGTGCTCCCCCGAGGGCTGCTGGGGCCCGGAGCCC
AGGGACTGCGTCTCTTGCCGGAATGTCAGCCGAGGCAGGGAATGCGTGGACAAGTGCAAC
CTTCTGGAGGGTGAGCCAAGGGAGTTTGTGGAGAACTCTGAGTGCATACAGTGCCACCCA
GAGTGCCTGCCTCAGGCCATGAACATCACCTGCACAGGACGGGGACCAGACAACTGTATC
CAGTGTGCCCACTACATTGACGGCCCCCACTGCGTCAAGACCTGCCCGGCAGGAGTCATG
GGAGAAAACAACACCCTGGTCTGGAAGTACGCAGACGCCGGCCATGTGTGCCACCTGTGC
CATCCAAACTGCACCTACGGATGCACTGGGCCAGGTCTTGAAGGCTGTCCAACGAATGGG
CCTAAGATCCCGTCCATCGCCACTGGGATGGTGGGGGCCCTCCTCTTGCTGCTGGTGGTG
GCCCTGGGGATCGGCCTCTTCATGCGAAGGCGCCACATCGTTCGGAAGCGCACGCTGCGG
AGGCTGCTGCAGGAGAGGGAGCTTGTGGAGCCTCTTACACCCAGTGGAGAAGCTCCCAAC
CAAGCTCTCTTGAGGATCTTGAAGGAAACTGAATTCAAAAAGATCAAAGTGCTGGGCTCC
GGTGCGTTCGGCACGGTGTATAAGGGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATT
CCCGTCGCTATCAAGGAATTAAGAGAAGCAACATCTCCGAAAGCCAACAAGGAAATCCTC
GATGAAGCCTACGTGATGGCCAGCGTGGACAACCCCCACGTGTGCCGCCTGCTGGGCATC
TGCCTCACCTCCACCGTGCAGCTCATCACGCAGCTCATGCCCTTCGGCTGCCTCCTGGAC
TATGTCCGGGAACACAAAGACAATATTGGCTCCCAGTACCTGCTCAACTGGTGTGTGCAG
ATCGCAAAGGGCATGAACTACTTGGAGGACCGTCGCTTGGTGCACCGCGACCTGGCAGCC
AGGAACGTACTGGTGAAAACACCGCAGCATGTCAAGATCACAGATTTTGGGCTGGCCAAA
CTGCTGGGTGCGGAAGAGAAAGAATACCATGCAGAAGGAGGCAAAGTGCCTATCAAGTGG
ATGGCATTGGAATCAATTTTACACAGAATCTATACCCACCAGAGTGATGTCTGGAGCTAC
GGGGTGACCGTTTGGGAGTTGATGACCTTTGGATCCAAGCCATATGACGGAATCCCTGCC
AGCGAGATCTCCTCCATCCTGGAGAAAGGAGAACGCCTCCCTCAGCCACCCATATGTACC
ATCGATGTCTACATGATCATGGTCAAGTGCTGGATGATAGACGCAGATAGTCGCCCAAAG
TTCCGTGAGTTGATCATCGAATTCTCCAAAATGGCCCGAGACCCCCAGCGCTACCTTGTC
ATTCAGGGGGATGAAAGAATGCATTTGCCAAGTCCTACAGACTCCAACTTCTACCGTGCC
CTGATGGATGAAGAAGACATGGACGACGTGGTGGATGCCGACGAGTACCTCATCCCACAG
CAGGGCTTCTTCAGCAGCCCCTCCACGTCACGGACTCCCCTCCTGAGCTCTCTGAGTGCA
ACCAGCAACAATTCCACCGTGGCTTGCATTGATAGAAATGGGCTGCAAAGCTGTCCCATC
AAGGAAGACAGCTTCTTGCAGCGATACAGCTCAGACCCCACAGGCGCCTTGACTGAGGAC
AGCATAGACGACACCTTCCTCCCAGTGCCTGAATACATAAACCAGTCCGTTCCCAAAAGG
CCCGCTGGCTCTGTGCAGAATCCTGTCTATCACAATCAGCCTCTGAACCCCGCGCCCAGC
AGAGACCCACACTACCAGGACCCCCACAGCACTGCAGTGGGCAACCCCGAGTATCTCAAC
ACTGTCCAGCCCACCTGTGTCAACAGCACATTCGACAGCCCTGCCCACTGGGCCCAGAAA
GGCAGCCACCAAATTAGCCTGGACAACCCTGACTACCAGCAGGACTTCTTTCCCAAGGAA
GCCAAGCCAAATGGCATCTTTAAGGGCTCCACAGCTGAAAATGCAGAATACCTAAGGGTC
GCGCCACAAAGCAGTGAATTTATTGGAGCATGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF07714</identifier>
        <name>Pkinase_Tyr</name>
      </pfam>
      <pfam>
        <identifier>PF00757</identifier>
        <name>Furin-like</name>
      </pfam>
      <pfam>
        <identifier>PF01030</identifier>
        <name>Recep_L_domain</name>
      </pfam>
      <pfam>
        <identifier>PF14843</identifier>
        <name>GF_recep_IV</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endocytic vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>receptor complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nuclear membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>perinuclear region of cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>Golgi membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>multivesicular body, internal vesicle lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>Shc-EGFR complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>basolateral plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>focal adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>early endosome membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell surface</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endosome membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane raft</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>transmembrane signaling receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>identical protein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein phosphatase binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>ubiquitin protein ligase binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>chromatin binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>double-stranded DNA binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein tyrosine kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>MAP kinase kinase kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>epidermal growth factor-activated receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>ATP binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>enzyme binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein heterodimerization activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>transmembrane receptor protein tyrosine kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>actin filament binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor signaling protein tyrosine kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of peptidyl-tyrosine phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Fc-epsilon receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neurotrophin TRK receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of nitric oxide biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of catenin import into nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of transcription from RNA polymerase II promoter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>embryonic placenta development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>salivary gland morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>ossification</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to amino acid stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Ras protein signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>single organismal cell-cell adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein insertion into membrane</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of DNA replication</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to epidermal growth factor stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vascular endothelial growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cerebral cortex cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>digestive tract morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein kinase B signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of phospholipase C activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of nitric-oxide synthase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>hair follicle development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of DNA repair</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>axon guidance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of MAP kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>learning or memory</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of MAPKK activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small GTPase mediated signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of fibroblast proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>epidermal growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of epithelial cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibroblast growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell surface receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phosphatidylinositol-mediated signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of phospholipase A2 activity by calcium-mediated signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>insulin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to estradiol stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to stress</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of ERK1 and ERK2 cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>morphogenesis of an epithelial fold</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>peptidyl-tyrosine phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>MAPK cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of protein catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of epidermal growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein autophosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to UV-A</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of apoptotic process</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
